Nitric oxide enhances expression and shedding of tumor necrosis factor receptor I (p55) in endothelial cells

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 20, Issue 6, 2000, Pages 1506-1511

  Okuyama, Masaki ^a   Yamaguchi, Seiji ^a   Yamaoka, Minako ^a   Nitobe, Joji ^a   Fujii, Satoshi ^b   Yoshimura, Tetsuhiko ^b   Tomoike, Hitonobu ^a  

^a YAMAGATA UNIVERSITY   (Japan)

^b Inst for Life Support Technology   (Japan)

Author keywords

Human endothelial cells; Nitric oxide; TNF receptor (p55); TNF ; Tyrosine kinase inhibitor

Indexed keywords

8 BROMO CYCLIC GMP; DIETHYLAMINE; GENISTEIN; HERBIMYCIN A; MATRIX METALLOPROTEINASE INHIBITOR; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE DONOR; PEROXYNITRITE; PROTEIN P55; PROTEIN TYROSINE KINASE INHIBITOR; TUMOR NECROSIS FACTOR RECEPTOR;

ARTICLE; CELL LINE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN DOMAIN; UMBILICAL VEIN;

EID: 0034080134     PISSN: 10795642     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.ATV.20.6.1506     Document Type: Article

References (57)

1. Levine B, Kalman J, Mayer L, Fillit HM, Packer M. Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990;323:236-241.
2. McMurray J, Abdullah I, Dargie HJ, Shapiro D. Increased concentrations of tumor necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J. 1991;66:356-358.
3. Dutka DP, Elborn JS, Delamere F, Shale DL, Morris GK. Tumor necrosis factor-α in severe congestive cardiac failure. Br Heart J. 1993;70: 141-143.
4. Ming WJ, Bersani L, Mantovani A. Tumor necrosis factor is chemotactic for monocytes and polymorphonuclear leukocytes. J Immunol. 1987;138: 1469-1474.
5. Barath P, Fishbein MC, Cao J, Berenson J, Helfant RH, Forrester JS. Detection and localization of tumor necrosis factor in human atheroma. Am J Cardiol. 1990;65:297-302.
6. Finkel MS, Oddis CV, Jacob TD, Watkins SC, Hattler BG, Simmons RL. Negative inotropic effects of cytokines on the heart mediated by nitric oxide. Science. 1992;257:387-389.
7. Yokoyama T, Vaca L, Rossern RD, Durante W, Hazarika P, Mann DL. Cellular basis for the negative inotropic effects of tumor necrosis factor-α in the adult mammalian heart. J Clin Invest. 1993;92:2303-2312.
8. Kubota T, McTiernan CF, Frye CS, Slawson SE, Lemster BH, Koretsky AP, Demetris AJ, Feldman AM. Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res. 1997;81:627-635.
9. Bozkurt BB, Kribbs SB, Clubb FJ, Michael LH, Didenko VV, Hornsby PJ, Seta Y, Oral H, Spinale FG, Mann DL. Pathophysiologically relevant concentrations of tumor necrosis factor-α promote progressive left ventricular dysfunction and remodeling in rats. Circulation. 1998;97: 1382-1391.
10. LeBoeuf RC, Schreyer SA. The role of tumor necrosis factor-α receptors in atherosclerosis. Trends Cardiovasc Med. 1998;8:131-138.
11. Vandenabeele P, Declercq W, Beyaert R, Fiers W. Two tumor necrosis factor receptors: structure and function. Trends Cell Biol. 1995;5: 392-399.
12. Engelmann H, Novick D, Wallach D. Two tumor necrosis factor-binding proteins purified from human urine: evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem. 1990;265:1531-1536.
13. Engelmann H, Aderka D, Rubinstein M, Rotman D, Wallach D. A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem. 1989;264:11974-11980.
14. Kapadia S, Torre-Anione G, Yokoyama T, Mann DL. Soluble TNF binding proteins modulate the negative inotropic properties of TNF-α in vitro. Am J Physiol. 1995;268:H517-H525.
15. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI, Jackson CG, Lange M, Burge DJ. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med. 1999; 340:253-259.
16. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, Mann DL. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (Enbrel, Etanercept) in patients with advanced heart failure. Circulation. 1999;99:3224-3226.
17. Ferrari R, Bachetti T, Confortini R, Opasich C, Febo O, Corti A, Cassani G, Visioli O. Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation. 1995;92: 1479-1486.
18. Nozaki N, Yamaguchi S, Shirakabe M, Nakamura H, Tomoike H. Soluble tumor necrosis factor receptors are elevated in relation to severity of congestive heart failure. Jpn Circ J. 1997;61:657-664.
19. Nozaki N, Yamaguchi S, Yamaoka M, Okuyama M, Nakamura H, Tomoike H. Enhanced expression and shedding of tumor necrosis factor (TNF) receptors from mononuclear leukocytes in human heart failure. J Mol Cell Cardiol. 1998;30:2003-2012.
20. Hwang C, Gatanaga M, Granger GA, Gatanaga T. Mechanism of release of soluble forms of tumor necrosis factor/lymphotoxin receptors by phorbol myristate acetate-stimulated human THP-1 cells in vivo. J Immunol. 1993;151:5631-5638.
21. Lantz M, Bjornberg F, Olsson I, Richter J. Adherence of neutrophils induces release of soluble tumor necrosis factor receptor forms. J Immunol. 1994;152:1362-1369.
22. Higuchi M, Aggarwal BB. TNF induces internalization of the p60 receptor and shedding of the p80 receptor. J Immunol. 1994;152: 3550-3558.
23. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature. 1988;333:664-666.
24. Mellion BT, Ignarro LJ, Ohlstein EH, Pontecorvo EG, Hyman AL, Kadowitz PJ. Evidence for the inhibitory role of guanosine 3′,5′-monophosphate in ADP-induced human platelet aggregation in the presence of nitric oxide and related vasodilators. Blood. 1981;57: 946-955.
25. Cooke JP, Singer AH, Tsao P, Zera P, Rowan RA, Billingham ME. Antiatherogenic effects of L-arginine in the hypercholesterolemic rabbit. J Clin Invest. 1992;90:1168-1172.
26. Moilanen E, Vapaatalo H. Nitric oxide in inflammation and immune response. Ann Med. 1995;27:359-367.
27. Corbett JA, Sweetland MA, Wang JL, Lancaster JR, MacDaniel ML. Nitric oxide mediates cytokine-induced inhibition of insulin secretion by human islets of Langerhans. Proc Natl Acad Sci USA. 1993;90: 1731-1735.
28. Hishikawa K, Nakaki T, Suzuki H, Kato H, Saruta T. Role of L-arginine-nitric oxide pathway in hypertension. J Hypertens. 1993;11:639-645.
29. Drexler H. Endothelium as a therapeutic target in heart failure [Review]. Circulation. 1998;98:2652-2655.
30. Winlaw DS, George AS, Anne MK, Christopher GS, Phillip MS, Peter SM. Increased nitric oxide production in heart failure. Lancet. 1994;344: 373-374.
31. Habib FM, Dutka D, Crossman D, Oarkley CM, Cleland JG. Enhanced basal nitric oxide production in heart failure. Lancet. 1994;344:371-373.
32. Takahashi K, Sawasaki Y, Hata J, Mukai K, Goto T. Spontaneous transformation and immortalization of human endothelial cells. In Vitro Cell Dev Biol. 1990;26:265-274.
33. Maier JAM, Statuto M, Ragnotti G. Endogenous interleukin 1α must be transported to the nucleus to exert its activity in human endothelial cells. Mol Cell Biol. 1994;14:1845-1851.
34. Hughes SE. Functional characterization of the spontaneously transformed human umbilical vein endothelial cell line ECV304: use in an in vitro model of angiogenesis. Exp Cell Res. 1996;225:171-185.
35. Hrabie JA, Klose R, Wink DA, Keefer LK. New nitric oxide-releasing zwitterions derived from polyamines. J Org Chem. 1993;58:1472-1476.
36. Gelperin A. Nitric oxide mediates network oscillations of olfactory interneurons in a terrestrial mollusc. Nature. 1994;369:61-63.
37. Kayagaki N, Kawasaki A, Ebata T, Ohmoto H, Ikeda S, Inoue S, Yoshino K, Okumura K, Yagita H. Metalloproteinase-mediated release of human Fas ligand. J Exp Med. 1995;182:1777-1783.
38. Yamada K, Nabeshima T. Simultaneous measurement of nitrite and nitrate levels as indices of nitric oxide release in the cerebellum of conscious rats. J Neurochem. 1997;68:1234-1243.
39. Yoshimura T, Yokayama H, Fujii S, Takayama F, Oikawa K, Kamada H. In vivo EPR detection and imaging of endogenous nitric oxide in lipopolysaccharide-treated mice. Nat Biotechnol. 1996;14:992-994.
40. Fujii S, Yoshimura T, Kamada H. Nitric oxide trapping efficiencies of water-soluble iron (III) complexes with dithiocarbamate derivatives. Chem Lett. 1996:785-786.
41. Nakamura H, Hino T, Kato S, Shibata Y, Takanashi H, Tomoike H. Tumor necrosis factor receptor gene expression in human whole lung tissue and pulmonary epithelium. Eur Respir J. 1996;9:1643-1647.
42. Marla SS, Lee J, Groves JT. Peroxynitrite rapidly permeates phospholipid membranes. Proc Natl Acad Sci USA. 1997;94:14243-14248.
43. Deleuran BW, Chu CQ, Field M, Mitchell T, Feldman M, Maini RN. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: implications for local actions of tumor necrosis factor α. Arthritis Rheum. 1992;35:1170-1178.
44. Torre-Amione G, Kapadia S, Lee J, Bies RD, Lebovitz R, Mann DL. Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation. 1995;92:1487-1493.
45. Caldwell J, Emerson SG. Interleukin-1α upregulates tumor necrosis factor receptors. Blood. 1995;86:3364-3372.
46. 2 peptide. Proc Natl Acad Sci USA. 1996;93:3377-3382.
47. Abe J, Berk BC. Reactive oxygen species as mediators of signal transduction in cardiovascular disease. Trends Cardiovasc Med. 1998;8: 59-64.
48. Baechowsky A, Munro SR, Morana SJ, Vincenti MP, Tredwell M. Oxidant-sensitive and phosphorylation-dependent activation of NF-κB and AP-1 in endothelial cells. Am J Physiol. 1995;269:L829-L836.
49. Pfeilschifter J, Huwiler A. Nitric oxide stimulates stress-activated protein kinases in glomerular endothelial and mesangial cells. FEBS Lett. 1996; 396:67-70.
50. Mullberg J, Durie FH, Otton-Evans C, Alderson MR, Rose-John S, Cosman D, Black RA, Mohler KM. A metalloproteinase inhibitor blocks shedding of the IL-6 receptor and the p60 receptor. J Immunol. 1995; 155:5198-5205.
51. Crowe PD, Walter BN, Mohler KM, Otten-Evans C, Black RA, Ware CF. A metalloprotease inhibitor blocks shedding of the 80-kD TNF receptor and TNF processing in T lymphocytes. J Exp Med. 1995;181:1205-1210.
52. Unglaub R, Maxeiner B, Thoma B, Pfizenmainer K, Scheurich P. Down-regulation of tumor necrosis factor (TNF) sensitivity via modulation of TNF binding capacity by protein kinase C activators. J Exp Med. 1987; 166:1788-1797.
53. Lantz M, Gullberg U, Nilsson E, Olsson I. Characterization in vitro of a human tumor necrosis factor-binding protein: a soluble form of a tumor necrosis factor receptor. J Clin Invest. 1990;86:1396-1413.
54. Gopalakrishna R, Chen ZH, Gundimeda U. Nitric oxide and nitric oxide-generating agents induce a reversible inactivation of protein kinase C activity and phorbol ester binding. J Biol Chem. 1993;268:27180-27185.
55. Vecchi M, Rudolph-Owen LA, Brown CL, Dempsey PJ, Carpenter G. Tyrosine phosphorylation and proteolysis. J Biol Chem. 1998;273: 20589-20595.
56. Werb Z, Yan Y. A cellular striptease act. Science. 1998;282:1279-1280.
57. Peschon JJ, Slack JL, Reddy P, Stocking KL, Sunnarborg SW, Lee DC, Russell WE, Castner BJ, Johnson RS, Fitzner JN, Boyce RW, Nelson N, Kozlosky CJ, Wolfson MF, Rauch CT, Cerretti DP, Paxton RJ, March CJ, Black RA. An essential role for ectodomain shedding in mammalian development. Science. 1998;282:1281-1284.